Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:GHRS NASDAQ:GMTX NASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$19.79-3.7%$20.93$19.00▼$26.58$2.52B0.851.45 million shs2.70 million shsGHRSGH Research$14.02+0.6%$14.12$6.00▼$20.50$702.38M0.97239,576 shs148,721 shsGMTXGemini Therapeutics$61.40+2.9%$58.05$1.16▼$14.10$2.66B-0.12189,291 shs356,331 shsIMVTImmunovant$16.70+10.8%$16.29$12.72▼$34.47$2.56B0.451.08 million shs4.33 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-3.65%-1.98%-8.93%-21.96%+0.25%GHRSGH Research+0.65%+2.86%+4.32%+11.18%+42.92%GMTXGemini Therapeutics+2.94%+2.70%+4.12%+29.75%+20.82%IMVTImmunovant+10.82%+10.01%+3.79%+4.24%-45.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.9062 of 5 stars3.62.00.03.92.83.33.8GHRSGH Research1.711 of 5 stars3.42.00.00.02.10.80.0GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant2.7384 of 5 stars4.41.00.00.02.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$33.2067.76% UpsideGHRSGH Research 2.88Moderate Buy$32.00128.25% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AIMVTImmunovant 2.83Moderate Buy$35.20110.78% UpsideCurrent Analyst Ratings BreakdownLatest GHRS, IMVT, GMTX, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025CPRXCatalyst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/12/2025IMVTImmunovantJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $37.008/12/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $30.008/11/2025IMVTImmunovantCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/28/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$17.00 ➝ $18.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$39.006/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M4.93$2.35 per share8.42$6.99 per share2.83GHRSGH ResearchN/AN/AN/AN/A$5.83 per shareN/AGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AIMVTImmunovantN/AN/AN/AN/A$3.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.6511.999.290.8437.36%40.78%35.36%11/5/2025 (Estimated)GHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AIMVTImmunovant-$413.84M-$2.85N/AN/AN/AN/A-80.99%-72.23%11/6/2025 (Estimated)Latest GHRS, IMVT, GMTX, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2026IMVTImmunovant-$0.69-$0.60+$0.09-$0.71N/AN/A8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AGHRSGH ResearchN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.716.55GHRSGH ResearchN/A29.4929.49GMTXGemini TherapeuticsN/A71.4971.49IMVTImmunovantN/A12.3212.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%GHRSGH Research56.90%GMTXGemini Therapeutics75.42%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%GHRSGH ResearchN/AGMTXGemini Therapeutics12.90%IMVTImmunovant1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableGHRSGH Research1052.03 millionN/AOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableIMVTImmunovant120174.32 million171.18 millionOptionableGHRS, IMVT, GMTX, and CPRX HeadlinesRecent News About These CompaniesRoivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript3 hours ago | seekingalpha.comImmunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease PatientsSeptember 3 at 12:57 PM | globenewswire.comOMERS ADMINISTRATION Corp Acquires Shares of 48,300 Immunovant, Inc. $IMVTSeptember 3 at 4:42 AM | marketbeat.comFinancial Survey: Immunovant (NASDAQ:IMVT) & Adlai Nortye (NASDAQ:ANL)September 3 at 2:11 AM | americanbankingnews.comImmunovant, Inc. $IMVT Holdings Boosted by Alpine Global Management LLCSeptember 2 at 8:55 AM | marketbeat.comRafferty Asset Management LLC Acquires 22,213 Shares of Immunovant, Inc. $IMVTSeptember 2 at 5:05 AM | marketbeat.comDAFNA Capital Management LLC Purchases 62,000 Shares of Immunovant, Inc. $IMVTSeptember 1 at 7:26 AM | marketbeat.com233,985 Shares in Immunovant, Inc. $IMVT Purchased by Nuveen LLCAugust 30, 2025 | marketbeat.comRoivant Sciences (ROIV) Announces Q1 2025 Business UpdateAugust 29, 2025 | finance.yahoo.comAnalysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $35.20August 29, 2025 | americanbankingnews.comImmunovant Stockholders Approve Key Governance DecisionsAugust 28, 2025 | tipranks.comImmunovant, Inc. $IMVT Shares Purchased by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.comJump Financial LLC Raises Stock Holdings in Immunovant, Inc. $IMVTAugust 28, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 28, 2025 | marketbeat.comIMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law FirmAugust 27, 2025 | businesswire.comCharles Schwab Investment Management Inc. Grows Position in Immunovant, Inc. $IMVTAugust 26, 2025 | marketbeat.comSwiss National Bank Acquires 30,800 Shares of Immunovant, Inc. $IMVTAugust 25, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Increases Holdings in Immunovant, Inc. $IMVTAugust 24, 2025 | marketbeat.comVanguard Group Inc. Raises Stock Holdings in Immunovant, Inc. $IMVTAugust 24, 2025 | marketbeat.comAberdeen Group plc Increases Stock Position in Immunovant, Inc. $IMVTAugust 21, 2025 | marketbeat.comDeutsche Bank AG Raises Stake in Immunovant, Inc. (NASDAQ:IMVT)August 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGHRS, IMVT, GMTX, and CPRX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$19.79 -0.75 (-3.65%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$19.95 +0.16 (+0.81%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.GH Research NASDAQ:GHRS$14.02 +0.09 (+0.65%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$14.00 -0.01 (-0.11%) As of 09/3/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Gemini Therapeutics NASDAQ:GMTX$61.40 +1.76 (+2.94%) As of 09/2/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Immunovant NASDAQ:IMVT$16.70 +1.63 (+10.82%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$16.74 +0.04 (+0.21%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
